- Home
- FIVE vs MDGL Comparison
FIVE vs MDGL Comparison
Compare FIVE & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FIVE | MDGL |
|---|---|---|
| Founded | 2002 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Department/Specialty Retail Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.8B | 9.6B |
| IPO Year | 2012 | N/A |
Fundamental Metrics
Financial Performance| Metric | FIVE | MDGL |
|---|---|---|
| Price | $164.09 | $583.34 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 17 | 13 |
| Target Price | $154.71 | ★ $543.33 |
| AVG Volume (30 Days) | ★ 1.3M | 368.6K |
| Earning Date | 12-03-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 4.95 | N/A |
| Revenue | ★ $4,231,969,000.00 | $740,640,000.00 |
| Revenue This Year | $20.21 | $395.75 |
| Revenue Next Year | $9.87 | $65.73 |
| P/E Ratio | $32.12 | ★ N/A |
| Revenue Growth | 13.88 | ★ 864.21 |
| 52 Week Low | $52.38 | $265.00 |
| 52 Week High | $168.98 | $605.00 |
Technical Indicators
Market Signals| Indicator | FIVE | MDGL |
|---|---|---|
| Relative Strength Index (RSI) | 61.52 | 68.11 |
| Support Level | $158.86 | $569.04 |
| Resistance Level | $167.92 | $598.77 |
| Average True Range (ATR) | 6.23 | 26.89 |
| MACD | 1.14 | -0.62 |
| Stochastic Oscillator | 84.20 | 82.64 |
Price Performance
Historical ComparisonAbout FIVE Five Below Inc.
Five Below Inc is a specialty value retailer offering merchandise targeted at the tween and teen demographic. The Company's edited assortment of products includes select brands and licensed merchandise. It derives revenue from sales of the Company's merchandise to customers.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.